Memantine: A review of possible uses in child and adolescent psychiatry

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Volumn 22, Issue 2, 2013, Pages 166-171

  Hosenbocus, Sheik ^a   Chahal, Raj ^a  

^a ROYAL INLAND HOSPITAL   (Canada)

Author keywords

Adolescents; Children; Glutamatergic system; Memantine; Nmda receptor antagonist; Pharmacology

Indexed keywords

CITALOPRAM; CLOZAPINE; ESCITALOPRAM; FLUOXETINE; LAMOTRIGINE; MEMANTINE; PLACEBO; RISPERIDONE; SERTRALINE;

ADD ON THERAPY; ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BINGE EATING DISORDER; BIPOLAR DISORDER; CATATONIC SCHIZOPHRENIA; CHILD; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERTENSION; INFANT; MAJOR DEPRESSION; MALE; MAXIMUM PLASMA CONCENTRATION; OBSESSIVE COMPULSIVE DISORDER; PRESCHOOL CHILD; SCHIZOPHRENIA; SCHOOL CHILD; SINGLE DRUG DOSE; SOMNOLENCE; SYSTEMATIC REVIEW;

EID: 84876933750     PISSN: 17198429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Aboujaoude, E., Barry, J., & Gamel, M. (2009). Memantine augmentation in treatment-resistant obsessive compulsive disorder: An open label trial. Journal of Clinical Psychopharmacology, 29(1), 51-55.
2. Anand, A., Gunn, A., Barkay, G., Karne, H., Nurnberger, J., Matthew, S., & Ghosh, S. (2012). Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: A double-blind, randomized, placebo-contolled trial. Bipolar Disorders, 14 (1), 64-70.
3. Berman, R., Capiello, A., Anand, A., Oren, D., Heninger, G., Charney, D., & Krystal, J. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47(4), 351-354.
4. Brennan, B., Roberts, J., Fogarty, K., Reynolds, K., Jonas, J., & Hudson, J. (2008). Memantine In the treatment of binge eating disorder: An open-label, prospective trial. International Journal of Eating Disorders, 41(6), 520-526.
5. Carlsson, M. (2000). On the role of cortical glutamine in obsessivecompulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatrica Scandinavica, 102(6), 401-413.
6. Carroll, B., Thomas, C., & Jayanti, K. (2006). Amantadine and memantine in catatonic schizophrenia. Annals of Clinical Psychiatry, 18(2), 133-134.
7. Carrey, N., MacMaster, F., Sparkes, S., Khan, S., & Kusumakar, V. (2002). Glutamatergic changes with treatment in attention deficit hyperactivity disorder: A preliminary case series. Journal of Child and Adolescent Psychopharmacology, 12(4), 331-336.
8. Carrey, N., MacMaster, F., Gaudet, L., & Schmidt, M. (2007). Striatal creatine and glutamate/glutamine in attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 17(1), 11-17.
9. Cerullo, M., Eliassen, J., & Nasrallah, H. (2007). Memantine normalizes brain activity in the inferior gyrus: A controlled pilot fMRI study. Schizophrenia Research, 97(1-3), 294-296.
10. Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S., (2005). Glutamatergic dysfunction in OCD. Neuropsychopharmacology, 30 (9), 1735-1740.
11. Cortese, B., & Phan, K., (2005). The role of glutamate in anxiety and related disorders. CNS Spectrums, 10(10), 820-830.
12. Chez, M., Burton, Q., Dowling, T., Change, M., Khanna, P., & Kramer, C. (2007). Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. Journal of Child Neurology, 22(5), 574-579.
13. de Lucena, D., Fernandes, B., Berk, M, Dodd, S., Medeiros, D., Pedrini, M. Gama, C. (2009). Improvement of negative and positive symptoms in treatment-refractory schizophrenia: A double-blind, randomized, placebo-controlled trial with memantine as addon therapy to clozapine. Journal of Clinical Psychiatry, 70(10), 1416-1423.
14. Erikson, C., Posey, D., Stigler, K., Mullet, J., Katschke, A., & McDougle, C. (2007). A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology, 191(1), 141-147.
15. Ferguson, J., & Shingleton, R. (2007). An open-label, flexible dose study of memantine in major depressive disorder. Clinical Neuropharmacology, 30(3), 136-144.
16. Feusner, J., Kerwin, L., Saxena, S., & Bystritsky, A. (2009). Differential efficacy of memantine for obsessive-compulsive disorder vs generalized anxiety disorder: An open-label trial. Psychopharmacology Bulletin, 42(1), 81-93.
17. Findling, R., McNamara, N., Stansbrey, R., Maxhimer, R., Periciou, A., Mann, A., & Graham, S. (2007). A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. Journal of Child Adolescent Psychopharmacology, 17(1), 19-33.
18. Ghaleiha, A., Asadabadi, M., Mohammadi, M., Shahei, M., Tabrizi, M., Hajiaghaee, R., Akhondzadeh, S. (2012). Memantine as adjunctive treatment to risperidone in children with autistic disorder: A randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology, First view (1), 1-7.
19. Ghaleiha, A., Entezari, N., Modabbernia, A., Najand, B., Askari, N., Tabrizi, M., Akhondzadeh, S. (2013). Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study. Journal of Psychiatric Research, 47(2), 175-180.
20. Hezel, D., Beattie, K., & Stewart S. (2009). Memantine as an augmenting agent for severe pediatric OCD. American Journal of Psychiatry, 166(2), 237.
21. Kavirajan, H. (2009). Memantine: A comprehensive review of safety and efficacy. Drug Safety Evaluation, 8(1), 89-109.
22. Keck, P., Hsu, H., Papadakis, K., & Russo, J. (2009). Memantine efficacy and safety in patients with acute mania associated with bipolar 1 disorder: A pilot evaluation. Clinical Neuropharmacology, 32(4), 199-204.
23. Kim, J., Kornhuber, H., Schmid-Burgk W., & Holzmuller, B. (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neuroscience Letters, 20, 379-382.
24. Kollmar, R., Markovic, K., Thurauf, N., Schmitt, H., & Kornhuber, J. (2008). Ketamine followed by memantine for the treatment of major depression. Australian & New Zealand Journal of Psychiatry, 42(2), 170.
25. Kornhuber, J., Kennepohl, E., Bleich, S., Wiltfang, J., Kraus, T., Reulbach, U., & Meineke, I. (2007). Memantine Pharmacotherapy. A naturalistic study using a population pharmacokinetic approach. Clinical Pharmacokinetics, 46(7), 599-612.
26. Koukopoulos, A., Reginaldi, D., Serra, G., Koukopoulos, A. E., Sani, G., & Serra, G. (2010). Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder. Bipolar Disorders, 12(3), 348-349.
27. Koukopulos, A., Serra, G., Koukopoulos, A. E., & Serra, G. (2012). The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: Findings from a 12-month naturalistic trial. Journal of Affective Disorders, 136(1-2), 163-166.
28. Krivoy, A., Weizman, A., Laor, L., Hellinger, N., Zemishlany, Z., & Fischel, T. (2008). Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. European Neuropsychopharmacology, 18(2), 117-121.
29. Levine, J., Panchalingam, K., Rapoport, A., Gershon, S., McClure, R., & Pettegrew, J. (2000). Increased cerebrospinal fluid glutamine levels in depressed patients. Biology Psychiatry, 47(7), 586-593.
30. Lieberman, J., Papadakis, K., Csernansky, J., Litman, R., Volavka, J., Jia, X., & Gage, A. (2009). A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology, 34 (1), 1322-1329.
31. Maeng, S., & Zarate, C. (2007). The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Current Psychiatry Reports, 9(6), 467-474.
32. Muhonen, L., Lonnqvist, J., Juva, K., & Alho, H. (2008). Doubleblind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. Journal of Clinical Psychiatry, 69(3), 392-399.
33. Niederhofer, H. (2007). Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. Journal of Clinical Psychopharmacology, 27(3), 317.
34. Owley, T., Salt, J., Guter, S., Grieve, A., Walton, L., Ayuyao, N., Cook, E. (2006). A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 517-524.
35. Parsons, C., Danysz, W., & Quack, G. (1999). Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: A review of preclinical data. Neuropharmacology, 38(6), 735-767.
36. Rosenberg, D., Macmaster, F., Keshavan, M., Fitsgerald K., Stewart C., & Moore G. (2000). Decrease in caudate glutamatergic concentrations in pediatric obsessive compulsive disorder patients taking paroxetine. Journal of the American Academy of Child and Adolescent Psychiatry. 39(9), 1096-1103.
37. Sani, G., Serra, G., Kotzalidis, G., Romano, S., Tamorri, S., Manfredi, G., Giradi, P. (2012). The role of memantine in the treatment of psychiatric disorders other than the dementias: A review of current preclinical and clinical evidence. CNS Drugs, 26(8), 663-690.
38. Schwartz, T., Siddiqui, U., & Raza, S. (2012). Memantine as an augmentation therapy for anxiety disorders. Case Reports in Psychiatry, 2012(749796), 1-3.
39. Stewart, S., Jenike, E., Hezel, D., Stack, D., Dodman, N., Shuster, L., & Jenike, M. (2010). A single blinded case control study of memantine in severe obsessive compulsive disorder. Journal of Clinical Psychopharmacology, 30(1), 34-39.
40. Thomas, S., & Grossberg, G. (2009). Memantine: A review of studies into its safety and efficacy in treating alzheimer's disease and other dementias. Clinical Interventions in Aging, 4, (41), 367-377.
41. Zarate, C., Singh, J., Carlson, P., Brutsche, N., Ameli, R., Luckenbaugh, D., Manji, H. (2006). A randomized trial of an N-methyl-D-asparate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63(8), 856-864.
42. Zdanys, K., & Tampi, R. (2008). A systematic review of off-label uses of memantine for psychiatric disorders. Progress in Neuro- Psychopharmacology, 32(6), 1362-1374.